DSM reports 2014 results

Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: “DSM generated 3% organic growth and delivered a relatively solid EBITDA with good cash flow from operating activities, amongst others due to improved operating working capital management. This was achieved despite the fact that 2014 was not an easy year for DSM with substantial negative exchange rate effects and tough market conditions in Nutrition and caprolactam."  More>


DSM Investor Relations App for mobile devices

Always stay informed about us on your mobile device via the DSM Investor Relations App. The App is available for free at Apple's App Store for the iPhone and the iPad and at Google Play for Android mobile devices.

Share price and volume

Share price

€ 0.0 0.0%

More share info>

Subscribe to receive press releases via email Subscribe to our RSS feed

Factbook in PDF

DSM Factbook 2014

You have requested the following file:

Choose an option: